The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Open accessAbstract
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Cited by
Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01613-1 · Cited by 4,274
Self-citationCampo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., de Leval, L., Dirnhofer, S., et al. (2022) · Blood · doi:10.1182/blood.2022015851 · Cited by 1,608
Self-citation
Metadata
- Authors
- Kemps, P. G., Picarsic, J., Durham, B. H., Hélias-Rodzewicz, Z., Hiemcke-Jiwa, L., van den Bos, C., van de Wetering, M. D., van Noesel, C. J. M., van Laar, J. A. M., Verdijk, R. M., Flucke, U. E., Hogendoorn, P. C. W., Woei-A-Jin, F. J. S. H., Sciot, R., Beilken, A., Feuerhake, F., Ebinger, M., Möhle, R., Fend, F., Bornemann, A., Wiegering, V., Ernestus, K., Méry, T., Gryniewicz-Kwiatkowska, O., Dembowska-Baginska, B., Evseev, D. A., Potapenko, V., Baykov, V. V., Gaspari, S., Rossi, S., Gessi, M., Tamburrini, G., Héritier, S., Donadieu, J., Bonneau-Lagacherie, J., Lamaison, C., Farnault, L., Fraitag, S., Jullié, M.-L., Haroche, J., Collin, M., Allotey, J., Madni, M., Turner, K., Picton, S., Barbaro, P. M., Poulin, A., Tam, I. S., El Demellawy, D., Empringham, B., Whitlock, J. A., Raghunathan, A., Swanson, A. A., Suchi, M., Brandt, J. M., Yaseen, N. R., Weinstein, J. L., Eldem, I., Sisk, B. A., Sridhar, V., Atkinson, M., Massoth, L. R., Hornick, J. L., Alexandrescu, S., Yeo, K. K., Petrova-Drus, K., Peeke, S. Z., Muñoz-Arcos, L. S., Leino, D. G., Grier, D. D., Lorsbach, R., Roy, S., Kumar, A. R., Garg, S., Tiwari, N., Schafernak, K. T., Henry, M. M., van Halteren, A. G. S., Abla, O., Diamond, E. L., & Emile, J.-F.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2022-01-13
- Volume
- 139
- Issue
- 2
- Pages
- 256-280
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3209573575
- Cited by
- 163
- References
- 1
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. https://app.cochat.ai/papers/10.1182/blood.2021013338
- The paper
- Kemps, P. G., Picarsic, J., Durham, B. H., Hélias-Rodzewicz, Z., Hiemcke-Jiwa, L., van den Bos, C., van de Wetering, M. D., van Noesel, C. J. M., van Laar, J. A. M., Verdijk, R. M., Flucke, U. E., Hogendoorn, P. C. W., Woei-A-Jin, F. J. S. H., Sciot, R., Beilken, A., Feuerhake, F., Ebinger, M., Möhle, R., Fend, F., . . . Emile, J.-F. (2022). ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. https://doi.org/10.1182/blood.2021013338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.